Ozempic and Moujaro maker Eli Lilly sued stomach paralysis claims

Ozempic and Moujaro makers are sued over claims their weight-loss drugs permanently paralyzed their stomachs

  • The blockbuster drugmakers allegedly failed to warn of stomach paralysis risks
  • The lawsuit includes one patient but 400 others have reached out for legal help
  • READ MORE:  Ozempic effects left women vomiting years after stopping drug

The drug behemoths behind blockbuster obesity medications Mounjro and Ozempic have been sued over claims that they caused stomach paralysis. 

Personal injury firm Morgan & Morgan has taken the case on behalf of a 44-year-old Louisiana woman with diabetes who lost weight while taking the drugs, only to suffer later from severe stomach paralysis marked by such violent vomiting that she has lost some teeth and required multiple trips to the hospital. 

The suit against Eli Lilly and Novo Nordisk, which make Mounjaro and Ozempic respectively, alleges that the companies failed to warn consumers about the risk of gastroparesis, or paralysis of the stomach. 

Paul Pennock, one of the lawyers representing the Louisiana patient, said: ‘It is our opinion that these drugs are causing these problems. We think that the evidence is sufficient for us to be able to prove it or we would not have filed the case, and we intend to file many more in the coming days and weeks.

‘Her problems have been so severe that she’s been to the emergency room multiple times, including last weekend. She’s actually even thrown up so violently that she’s lost teeth.’ 

The causes of gastroparesis (stomach paralysis) are largely unknown, but it is thought to be a complication of diabetes, which is why many of these patients take Ozempic and its sister drug Wegovy in the first place

Wegovy and Ozempic work by triggering the body to produce a hormone called GLP-1 that is released naturally from the intestines after meals

The patient known only as Jaclyn starting taking Ozempic, initially meant for people with type II diabetes but was frequently prescribed ‘off label’ for weight loss, in the spring of 2022. 

She switched to Mounjaro, another medication that causes weight loss, in July 2023 after over a year of severe stomach problems such as severe, violent vomiting, a hallmark symptom of stomach paralysis. 

Stomach paralysis affects the spontanous movement of stomach muscles that are responsible for propelling food through the digestive tract. With impaired stomach muscles, food sits in the stomach for longer than it should without being completely digested. 

But the switch to Mounjaro did not make a difference, she told her lawyers. Mr Pennock said she stopped taking Mounjaro, a once weekly injectable, 10 days ago, while added that there have been many other patients with those issues for much longer than that after they stop taking Mounjaro or other GLP-1 drugs. 

The lawyer’s mention of the roughly 400 other patients who have enlisted the firm’s help in suing for damages of an unknown total suggests the drug behemoths could expect a wave of personal injury lawsuits. 

One such patient was Joanie Knight, 37, who started taking the blockbuster weight-loss drug in 2019 and began suffering from severe nausea and vomiting two years into taking the medication. 

She was diagnosed with stomach paralysis after the sickness became so bad she couldn’t eat. 

Her ordeal began on her birthday in 2021, when she found that she couldn’t swallow her food. ‘It felt like it was stuck in my throat,’ she said. 

Despite having eaten very little that day, the incident triggered severe vomiting. That first bout of sickness kicked off a pattern of severe nausea all the time, no matter how little she ate. She also took anti-nausea pills ‘like they were candy.’ 

Doctors performed a gastric emptying study, a test to figure out how much time it takes a meal to move through a person’s stomach. They found that after four hours, more than 35 percent of her food was still in her stomach. Normally, less than 10 percent remains after that long. 

Source: Read Full Article